Hong Ren; Di Xu; Lingxiao Qu; Xin Shen; Kaiyun Chen; Qichao Pan; Jiayu Hu; Yang Shi; Jian Li; Xin Chen; Hong Ren; Di Xu; Lingxiao Qu; Xin Shen; Kaiyun Chen; Qichao Pan; Jiayu Hu; Yang Shi; Jian Li; Xin Chen

doi:10.46234/ccdcw2025.137

[1]

World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Geneva: World Health Organization; 2016. https://www.who.int/publications/i/item/WHO-HIV-2016.06.

[2]

Luo ZB, Li LJ, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 2012;16(2):e82 − 8. https://doi.org/10.1016/j.ijid.2011.10.009.

[3]

Yin XR, Wang W, Chen H, Mao Q, Han GR, Yao L, et al. Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China. Nat Med 2024;30(2):455 − 62. https://doi.org/10.1038/s41591-023-02782-x.

[4]

Li J, Pang L, Liu ZF. Interpretation of the national action plan for eliminating hepatitis c as a public health threat (2021-2030). China CDC Wkly 2022;4(29):627 − 30. https://doi.org/10.46234/ccdcw2022.139.

[5]

World Health Organization. Updated recommendations on simplified service delivery and diagnostics for hepatitis C infection. Geneva: World Health Organization; 2022. https://www.who.int/publications/i/item/9789240052697.

[6]

Ren H, Shi Y, Meng W, Hu JY, Chen YH, Pan QC. Study of disease burden of chronic hepatitis B and C patients in Shanghai based on Bronfenbrenner’ s ecological systems theory: a community-based survey. Chin J Epidemiol 2017;38(1):37 − 42. https://doi.org/10.3760/cma.j.issn.0254-6450.2017.01.007.

[7]

Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol 2020;73(6):1368 − 78. https://doi.org/10.1016/j.jhep.2020.07.025.

[8]

Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Chin J Hepatology 2022;30(12):1309 − 31. https://doi.org/10.3760/cma.j.cn501113-20221204-00607.

[9]

World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024. https://www.who.int/publications/i/item/9789240091672.

[10]

Huang G, Li PP, Lau WY, Pan ZY, Zhao LH, Wang ZG, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. Ann Surg 2018;268(6):943 − 54. https://doi.org/10.1097/SLA.0000000000002727.

[11]

World Health Organization. Consolidated guidelines on person-centred viral hepatitis strategic information: using data to support country scale-up of hepatitis prevention, diagnosis and treatment services. Geneva: World Health Organization; 2024. https://www.who.int/publications/i/item/9789240091313.